For this, we measured functional connectivity by using resting MRI and presynaptic dopamine capacity by using [18F]DOPA PET in healthy volunteers (n=12) and patients with schizophrenia who were treated with first-line antipsychotic drugs (n=12) and clozapine (n=12), respectively.
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The Effects of An Atypical Antipsychotic on the Mr 32 kDa Related Signaling Pathways
Hanson Park, St. Andrew's Hospital, Republic of Korea Abstract Introduction: In this study, we investigated changes in phosphorylation of Mr 32 kDa and ERK1/2 related signaling pathways in rat striatum, which is closely related to development of extrapyramidal symptom, after intraperitoneal injection of risperidone, which is one of the representative atypical antipsychotics, to facilitate understanding of the action mechanism of antipsychotic agents and regulatory mechanism of signal transduction of neuronal cell. Methods: Risperidone (0.5, 2.0 mg/kg) was injected into the Sprague-Dawley rats intraperitoneally and control animals received an equivalent volume of 0.3% tartaric acid. Western blot analysis was carried out to investigate the changes in Mr 32 kDa and ERK1/2 related molecules in response to risperidone treatment. Results: After 15, 30, 60 and 120min from treatment of risperidone (0.5 mg/kg), phosphorylations of MEK1/2 (Ser217/Ser221) and ERK1/2 (Thr202/Tyr204) were not changed, significantly. After 30 min from treatment of risperidone (2.0 mg/kg), phosphorylations of MEK1/2 were increased, significantly. After 120 min from treatment of risperidone (2.0 mg/kg), phosphorylations of ERK1/2 were increased, significantly.
In terms of p90RSK (Thr360/Ser364), phosphorylations were increased after 30 and 60min from treatment of risperidone (2.0 mg/kg). Conclusions: Phosphorylations of ERK1/2, MEK1/2, and p90RSK were not changed after treatment of risperidone 0.5 mg/kg. Phosphorylations of ERK1/2, MEK1/2, and p90RSK after the injection of risperidone 2mg/kg were increased in some sample according to time-course. These findings suggest that risperidone may affect MEK1/2-ERK1/2-p90RSK pathway in the manner of time and dose specificity. In summary, time and dose dependant influence of risperidone on the signal transduction in striatum, which is responsible to the pathophysiology of schizophrenia and action mechanism of antipsychotics, might be related to unique properties of atypical antipsychotics include risperidone.
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Long term atypical antipsychotic treatment improves cognitive performance in schizophrenia but not surpassing conventional antipsychotic drugs effects.
Gabriel Selva Vera (1), Aroa Borrás Barrachina (2). (1) Teaching Unit of Psichiatry and Psychological Medicine. University of Valencia (Spain). (2) University Jaime I, Castellón (Spain).
Abstract Background and Objectives: Atypical antipsychotics provide better control of the negative and affective symptoms of schizophrenia when compared with conventional neuroleptics. Nevertheless, their heightened ability to improve cognitive dysfunction remains a matter of debate. This study aimed to examine the changes in cognition associated with long-term antipsychotic treatment and to evaluate the effect of the type of antipsychotic (conventional versus novel antipsychotic drugs) on cognitive performance over time. Methods: In this naturalistic study, we used a comprehensive neuropsychological battery of tests to assess a sample of schizophrenia patients taking either conventional (n = 21) or novel antipsychotics (n = 32) at baseline and at two years after.
These tests were used to measure seven neurocognitive domains, (Executive Functions, Working Memory, Verbal Memory, Visual Memory, Visual-Motor Processing, Semantic Verbal Fluency and Motor Speed).
The clinical evaluation of each patient was rated according to the Positive and Negative Symptom Scale and to the Hamilton Rating Scale for Depression. Premorbid adjustment was assessed using the Phillips Adjustment Scale.
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Results: Continuous antipsychotic treatment regardless of class was associated with improvement on verbal fluency, executive functions, and visual and verbal memory. The variable "type of antipsychotic" did not predict the improvement of performance in any of the neuropsychological tests, as assessed using regression analyses. However, intake of anticholinergic drugs seems to predict cognitive changes significantly. Conclusions: In the absence of other reasons to change ongoing treatment, which include negative or affective symptoms or lack of compliance with the regimen, the switch from typical APD at low or moderate doses to atypical APDs is not justified if based solely on the expectation of a more favorable cognitive outcome. Abstract Objective: For evidence-based activities for psychiatric rehabilitation in patients with chronic schizophrenia, preceding investigation to assess the pattern or characteristic on neuroplasticity is necessary. For this purpose, this study evaluated short-term response of serum Brain-Derived Neurotrophic Factor (sBDNF) to the quantified stimuli applied with repetitive Transcranial Magnetic Stimulation (rTMS). Methods: Right-handed twenty inpatients, with chronic schizophrenia, on stable medication whose minimum duration of illness was 10 years were recruited. The handedness was assessed using Edinburgh Handedness Inventory. Consecutive 10 weekday sessions with 20 Hz rTMS (a total of 20,000 stimuli) were applied over the left dorsolateral prefrontal cortex at 100% of motor threshold. There was no change in the medication for at least 2 week before enrollment and 4 weeks thereafter. Serum Prolactin level was co-measured for the reference of stable medication. Primary outcome measure was the change in the mean concentration of duplicated sBDNF(pg/ml). Clinical severity or change was measured using the Clinical Global Impression scale (CGI) and the Positive and Negative Symptom Scale (PANSS). Results: Eighteen participants (male, 10; female, 8) completed the study and were analyzed. The mean(SD) of chlorpromazine equivalent (CPZE) of antipsychotics were 1,325.69(761.58)mg. The mean(SD) of baseline CGI-severity and total PANSS score were 4.61(0.50) and 68.44(6.05), respectively. The differences from baseline, in the level of sBDNF, just after the completion of rTMS sessions, were statistically significant (paired t-test: t = 2.245, df =17, p = 0.038). At 2 weeks after the completion of rTMS sessions, however, the significance in the level of sBDNF was not manifest (t = 1.381, df = 17, p = 0.185).
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Conclusion:
The findings of this study suggest that, despite limited neuroplastic capacity of patients with chronic schizophrenia, neuroplastic change could be induced through continuous therapeutic stimuli, which might provide both optimistic and pessimistic implications to activities for psychiatric rehabilitation. Key words: chronic schizophrenia, neuroplasticity, serum BDNF, r TMS, rehabilitation <2016 CINP, Seoul, Korea, July 3-5, 2016 >
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The ECT Augmenting Effects for Patients with Clozapine-Resistant Schizophrenia
Hye Sung Kim, Se Hyun Kim, Tak Youn, In Won Chung, Yong Sik Kim Department of Neuropsychiatry and Institution of Clinical Psychopharmacology, Dongguk University International Hospital, Goyang-si, Gyeonggi-do, KOREA Abstract Objective: For the treatment of the patients with treatmentresistant schizophrenia, clozapine is recommended as the drug of choice, but still causes insufficient responses in 40 to 70 % of the patients having been treated with clozapine. The electroconvulsive therapy (ECT) might be an effective and safe option increasing clinical effects. This study was aimed to explore the ECT ugmenting effects for patients with clozapine-resistant schizophrenia. Methods: By using retrospective chart reviews, nine inpatients with clozapine-resistant schizophrenia who had received ECT at Dongguk University International Hospital were recruited. Clozapine resistance is defined as persistent psychotic symptoms despite of clozapine treatment at least for 12 weeks with blood clozapine levels over 350ng/ml. The bilateral electrode was applied and MECTA spECTrum 5000Q ® was used underg eneral anesthesia. We explored the changes of psychopathology with the PANSS through ECT and the correlational factors. Results: In nine patients, the mean reduction of the PANSS total score after ECT was 17.8 (SD = 11.6) which was significant (p = 0.0092). The mean reduction rate was 25.0 % (SD = 13.0) from the baseline using 0-6 rating system. The mean clozapine doses were 388.9 (SD = 153.1) mg before ECT and 286.1 (SD = 97.7) mg after ECT with no significant changes. The mean clozapine blood levels of nine patients were 632.2 (SD = 146.9) and 552.7 (SD = 216.4) ng/mL before and after ECT respectively with no significant changes. Six (67.8 %) patients showed responses with the traditional criteria of 20% reduction used in medicationresistant schizophrenia trials.
Conclusion:
The result of the retrospective case series report showed that ECT augmentation on clozapine-resistance had additional clinical benefits without any persistent adverse effects. The ECT augmentation can be a favorable strategy for the treatment of clozapine-resistant schizophrenia.
